Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2012-09-18 (13 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CHARLEVILLE-MEZIERES (08000), Ardennes
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE MANCHESTER : revenue, balance sheet and financial ratios
SELAS PHARMACIE MANCHESTER is a French company
founded 13 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CHARLEVILLE-MEZIERES (08000),
this company of category PME
shows in 2024 a net income positive of 170 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE MANCHESTER (SIREN 753971563)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
170 040 €
156 603 €
182 090 €
225 503 €
198 485 €
200 836 €
218 425 €
232 409 €
129 407 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELAS PHARMACIE MANCHESTER generates positive net income of 170 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 129 k€ -> 170 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
170 040 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 47%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 60%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
47.405%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
59.514%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELAS PHARMACIE MANCHESTER
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
262.258
163.25
111.32
79.787
63.868
52.874
63.243
56.686
47.405
Financial autonomy
24.715
33.482
42.453
49.954
55.258
59.182
56.01
56.938
59.514
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
47.412024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good
In 2024, the debt ratio of SELAS PHARMACIE MANCHESTER (47.41) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
59.51%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good
In 2024, the financial autonomy of SELAS PHARMACIE MANCHESTER (59.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 108.84. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
108.839
Liquidity indicators evolution SELAS PHARMACIE MANCHESTER
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
90.565
84.288
81.722
100.735
111.67
130.106
142.333
117.915
108.839
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
108.842024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Watch
In 2024, the liquidity ratio of SELAS PHARMACIE MANCHESTER (108.84) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Positioning of SELAS PHARMACIE MANCHESTER in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELAS PHARMACIE MANCHESTER is estimated at
2 373 884 €
(range 1 653 135€ - 3 551 466€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1653k€2373k€3551k€
2 373 884 €Range: 1 653 135€ - 3 551 466€
NAF 5 année 2024
Valuation method used
Net Income Multiple
170 040 €
×
14.0x
=2 373 884 €
Range: 1 653 135€ - 3 551 466€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE MANCHESTER with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE MANCHESTER
What is the revenue of SELAS PHARMACIE MANCHESTER ?
The revenue of SELAS PHARMACIE MANCHESTER is not publicly disclosed (confidential accounts filed with INPI).
Is SELAS PHARMACIE MANCHESTER profitable?
Yes, SELAS PHARMACIE MANCHESTER generated a net profit of 170 k€ in 2024.
Where is the headquarters of SELAS PHARMACIE MANCHESTER ?
The headquarters of SELAS PHARMACIE MANCHESTER is located in CHARLEVILLE-MEZIERES (08000), in the department Ardennes.
Where to find the tax return of SELAS PHARMACIE MANCHESTER ?
The tax return of SELAS PHARMACIE MANCHESTER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE MANCHESTER operate?
SELAS PHARMACIE MANCHESTER operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart